DCEG investigators regularly develop tools to predict risk of developing cancer. Many of these models are used in clinical settings to manage patient care, or assign patients to appropriate cancer screening.
DCEG researchers developed the Gail breast cancer risk assessment model (Gail et al., 1989) to estimate a woman's risk of developing invasive breast cancer. Since its original publication, the tool has been updated and expanded. It is widely used by clinicians and researchers. The Food and Drug Administration guidelines rely on the tool for the recommendation of use of tamoxifen and raloxifene for breast cancer risk reduction.
Researchers in DCEG developed a risk assessment tool for breast cancer utilizing modifiable and nonmodifiable factors (Maas et al 2016)
DCEG research has contributed to important milestones in the management of melanoma, including the creation of a clinical atlas depicting melanoma and precursor lesions, the creation of training videos to help health care providers examine high-risk families, and the development of a risk calculator to estimate an individual’s probability of developing melanoma (Tucker et al., 2002; Fears et al., 2006).